IRONWOOD PHARMACEUTICALS, INC. Proceeds from Long-term Lines of Credit
IRONWOOD PHARMACEUTICALS, INC. (IRWD) reported Proceeds from Long-term Lines of Credit of $150.00 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromLongTermLinesOfCredit · last filed 2026-02-26
- IRONWOOD PHARMACEUTICALS, INC. proceeds from long-term lines of credit for the quarter ending 2024-12-31 was $0.00.
- IRONWOOD PHARMACEUTICALS, INC. proceeds from long-term lines of credit for the quarter ending 2024-09-30 was $0.00.
- IRONWOOD PHARMACEUTICALS, INC. proceeds from long-term lines of credit for the quarter ending 2023-12-31 was $0.00.
- IRONWOOD PHARMACEUTICALS, INC. proceeds from long-term lines of credit for the quarter ending 2023-09-30 was $0.00.
- IRONWOOD PHARMACEUTICALS, INC. proceeds from long-term lines of credit for fiscal 2024 was $150.00M, a 62.50% decline from fiscal 2023.
- IRONWOOD PHARMACEUTICALS, INC. proceeds from long-term lines of credit for fiscal 2023 was $400.00M.
| Period end | Proceeds from Long-term Lines of Credit 3 month | Proceeds from Long-term Lines of Credit 6 month | Proceeds from Long-term Lines of Credit 9 month | Proceeds from Long-term Lines of Credit 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $150.00M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $150.00M 10-Q · filed 2025-11-10 | ||
| 2024-06-30 | $150.00M 10-Q · filed 2025-08-11 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $0.00 derived: sum of 2 quarters · filed 2025-03-31 | $400.00M 10-K · filed 2025-03-31 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $400.00M 10-Q · filed 2024-11-07 | ||
| 2023-06-30 | $400.00M 10-Q · filed 2024-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |